Evidence map›Paper›PMID 26349750›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Low 25-OH vitamin D levels at time of diagnosis and recurrence of ovarian cancer.

Teresa Granato, Lucia Manganaro, Luca Petri, Maria Grazia Porpora, Valentina Viggiani, Antonio Angeloni, Emanuela Anastasi

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. 1α,25(OH)Frontiers in pharmacology · 2020
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Teresa GranatoCNR-IBPM, National Research Council, Viale Regina Elena 324, 00161, Rome, Italy.
Lucia ManganaroDepartment of Radiological, Oncological, and Pathological Sciences, "Sapienza" University of Rome, Rome, Italy.
Luca PetriDepartment of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.
Maria Grazia PorporaDepartment of Gynecology, Obstetrics and Urology, "Sapienza" University of Rome, Rome, Italy.
Valentina ViggianiDepartment of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.
Antonio AngeloniDepartment of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.
Emanuela AnastasiDepartment of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy. emanuela.anastasi@uniroma1.it.
Sapienza University of Rome · ITNational Research Council · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this study was to evaluate the correlation between 25-OH vitamin D and ovarian cancer as a diagnostic marker or recurrence disease marker. We studied the following: (1) 61 women without gynecologic diseases, (2) 45 women affected by benign ovarian disease, (3) 46 women with recent diagnosis of ovarian cancer, (4) 26 follow-up women with recurrent ovarian cancer, and (5) 32 follow-up women with stable ovarian cancer. The 25-OH vitamin D was quantified with LUMIPULSE® G 25-OH vitamin D on LUMIPULSE® G 1200 (Fujirebio, Japan). As a threshold value, identified by ROC curve analysis, 20.2 ng/mL (sensitivity 73.3 %, specificity 84 %) was chosen corresponding to the limit between sufficient and insufficient 25-OH vitamin D according to the WHO. Low 25-OH vitamin D levels were observed in 26 % of women without gynecologic diseases, in 80 % of women with recent diagnosis of ovarian cancer and in 24 % women affected by benign ovarian diseases (p < 0.001). The follow-up study showed an insufficient level of 25-OH vitamin D in 73 % women with recurrent ovarian cancer and in 47 % women with stable ovarian cancer (p < 0.0003). This study showed that patients with ovarian cancer are often insufficient in 25-OH vitamin D compared to women with benign ovarian diseases. The women with recurrent ovarian cancer presented more often low levels compared to women with stable ovarian cancer. This study suggests that 25-OH vitamin D, due to its antiproliferative properties, can be a good marker for ovarian cancer also.

Indexed as

AdultAgedAged, 80 and overArea Under CurveBiomarkers, TumorCarcinoma, Ovarian EpithelialEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm Recurrence, LocalNeoplasms, Glandular and EpithelialOvarian NeoplasmsROC CurveSensitivity and Specificity25-hydroxyvitamin DBiomarkers, TumorVitamin D25-OH vitamin DBiomarkerEpithelial ovarian cancerFollow-up

Identifiers

PMID26349750
OpenAlexW1460640337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.